Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer.

Aghajanian, C; Dizon, D S; Sabbatini, P; Raizer, J J; Dupont, J; Spriggs, D R

Aghajanian, C; Dizon, D S; Sabbatini, P; Raizer, J J; Dupont, J; Spriggs, D R.

Affiliation

Aghajanian C; Developmental Chemotherapy Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA. aghajanc@mskcc.org

J Clin Oncol ; 23(25): 5943-9, 2005 Sep 01.

Article in En | MEDLINE | ID: mdl-16135465

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Neoplasm Recurrence, Local/drug therapy; Ovarian Neoplasms/drug therapy; Peritoneal Neoplasms/drug therapy; Aged; Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Boronic Acids/administration & dosage; Bortezomib; Carboplatin/administration & dosage; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local/pathology; Ovarian Neoplasms/pathology; Peritoneal Neoplasms/pathology; Pyrazines/administration & dosage

Search on Google

XML

PubMed Links

Collection: 01-internacional Health context: 3_ND Database: MEDLINE Main subject: Ovarian Neoplasms / Peritoneal Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Neoplasm Recurrence, Local Type of study: Prognostic_studies Limits: Aged / Female / Humans / Middle aged Language: En Journal: J Clin Oncol Year: 2005 Document type: Article

Search on Google

XML

PubMed Links